Medical Information
United States

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.
Not a healthcare professional? Go to the patient or caregiver website.

DEPO-PROVERA® CI Patient Counseling Information (medroxyprogesterone acetate injectable suspension, for intramuscular use)


"See FDA-approved patient labeling (Patient Information)."

  • Advise patients at the beginning of treatment that their menstrual cycle may be disrupted and that irregular and unpredictable bleeding or spotting results, and that this usually decreases to the point of amenorrhea as treatment with Depo-Provera CI continues, without other therapy being required.
  • Counsel patients about the possible increased risk of breast cancer in women who use Depo-Provera CI [see Warnings and Precautions (5.3)].
  • Counsel patients that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases.
  • Counsel patients on Warnings and Precautions associated with use of Depo-Provera CI.
  • Counsel patients to use a back-up method or alternative method of contraception when enzyme inducers are used with Depo-Provera CI.

This product's labeling may have been updated. For the most recent prescribing information, please visit

Did you find an answer to your question? Yes No
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event